These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7212946)

  • 21. Correlation of initial thiothixene serum levels and clinical response. Comparison of fluorometric, gas chromatographic, and RBC assays.
    Yesavage JA; Holman CA; Cohn R; Lombrozo L
    Arch Gen Psychiatry; 1983 Mar; 40(3):301-4. PubMed ID: 6830409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiothixene and the thioxanthenes.
    Ban TA; Lehmann HE
    Adv Biochem Psychopharmacol; 1974; 9(0):481-6. PubMed ID: 4836220
    [No Abstract]   [Full Text] [Related]  

  • 23. Proceedings: A comparative study of thiothixene and chlorpromazine in chronic schizophrenic patients: application of a special psychometric test battery.
    Ruiz-Navarro JF; Vergara L; Deutsch M
    Psychopharmacol Bull; 1976 Jan; 12(1):38-9. PubMed ID: 1108083
    [No Abstract]   [Full Text] [Related]  

  • 24. Subjective response to neuroleptics in schizophrenia.
    Awad AG
    Schizophr Bull; 1993; 19(3):609-18. PubMed ID: 7901897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haloperidol and thiothixene in the long-term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment.
    Engelhardt DM; Rudorfer L; Rosen B
    J Clin Psychiatry; 1978 Dec; 39(12):834-40. PubMed ID: 721787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma levels of thiothixene by radioreceptor assay: clinical usefulness.
    Van Putten T; May PR; Marder SR; Wilkins JN; Rosenberg BJ
    Psychopharmacology (Berl); 1983; 79(1):40-4. PubMed ID: 6403963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A preliminary attempt to relate individual differences in EEG test dose response to clinical effect.
    May PR; Itil T; Van Putten T; Lee MA; Yale C
    Biol Psychiatry; 1982 May; 17(5):599-603. PubMed ID: 7093395
    [No Abstract]   [Full Text] [Related]  

  • 28. Motility, Parkinsonism, and prolactin with thiothixene and thioridazine.
    Crowley TJ; Hydinger-Macdonald M
    Arch Gen Psychiatry; 1981 Jun; 38(6):668-75. PubMed ID: 7247630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia.
    Tandon R; Goldman RS; Goodson J; Greden JF
    Biol Psychiatry; 1990 Jun; 27(12):1323-6. PubMed ID: 2364120
    [No Abstract]   [Full Text] [Related]  

  • 30. Electrodermal activity and therapeutic response to neuroleptic treatment in chronic schizophrenic in-patients.
    Schneider SJ
    Psychol Med; 1982 Aug; 12(3):607-13. PubMed ID: 7134318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma levels and clinical effects of thioridazine and thiothixene.
    Bergling R; Mjorndal T; Oreland L; Rapp W; Wold S
    J Clin Pharmacol; 1975; 15(2-3):178-86. PubMed ID: 1091665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Akathisia with haloperidol and thiothixene.
    Van Putten T; May PR; Marder SR
    Arch Gen Psychiatry; 1984 Nov; 41(11):1036-9. PubMed ID: 6497564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum level monitoring of thiothixene in schizophrenia: acute single-dose levels at fixed doses.
    Yesavage JA; Becker J; Werner PD; Mills MJ; Holman CA; Cohn R
    Am J Psychiatry; 1982 Feb; 139(2):174-8. PubMed ID: 7055286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms.
    Taniguchi T; Sumitani S; Aono M; Iga J; Kinouchi S; Aki H; Matsushita M; Taniguchi K; Tsuno M; Yamanishi K; Tomotake M; Kaneda Y; Ohmori T
    Hum Psychopharmacol; 2006 Oct; 21(7):439-45. PubMed ID: 17029303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationship between depressive symptoms and subjective well-being in newly admitted patients with schizophrenia.
    Kim JH; Ann JH; Kim MJ
    Compr Psychiatry; 2010; 51(2):165-70. PubMed ID: 20152297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overlap between emotional blunting, depression, and extrapyramidal symptoms in schizophrenia.
    Müller M
    Schizophr Res; 2002 Oct; 57(2-3):307. PubMed ID: 12223263
    [No Abstract]   [Full Text] [Related]  

  • 38. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome.
    Awad AG; Voruganti LN; Heslegrave RJ; Hogan TP
    Int Clin Psychopharmacol; 1996 May; 11 Suppl 2():55-9. PubMed ID: 8803661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The assessment of thiothixene in chronic schizophrenia. A double-blind controlled trial.
    Burnett GB; Little SR; Graham N; Forrest AD
    Dis Nerv Syst; 1975 Nov; 36(11):625-9. PubMed ID: 1102277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid tranquilization: a comparison of thiothixene with loxapine.
    Dubin WR; Weiss KJ
    J Clin Psychiatry; 1986 Jun; 47(6):294-7. PubMed ID: 3711026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.